Format

Send to

Choose Destination
Eur J Pharmacol. 2006 Feb 15;531(1-3):282-4. Epub 2006 Jan 19.

Activation of cannabinoid CB1 receptors induces glucose intolerance in rats.

Author information

1
Fundación IMABIS, Hospital Carlos Haya, Avenida Carlos Haya s/n, 7(a) Planta, Pabellón A, Málaga 29010, Spain. franciscoj.bermudez.exts@juntadeandalucia.es

Abstract

Recent reports have described the presence of cannabinoid CB1 receptors in pancreatic islets. Here we show that administration of the endogenous cannabinoid anandamide or the selective cannabinoid CB1 receptor agonist Arachidonyl-2'-chloroethylamide (ACEA) results in glucose intolerance after a glucose load. This effect is reversed by the selective cannabinoid CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251). These results suggest that targeting cannabinoid CB1 receptors may serve as new therapeutic alternatives for metabolic disorders such as diabetes.

PMID:
16423347
DOI:
10.1016/j.ejphar.2005.12.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center